Aviv Scientific
Cognitive and Functional Decline Treatment Solutions
Company Overview
Snapshot
Founded in July 2017 by Shai Efrati, Jonathan Preminger, and Michael Lobel, Aviv Scientific operates with 11–50 employees. The company has raised $62 million across two funding rounds from three investors. In September 2021, Aviv Scientific secured a funding round from Deep Insight.
Business overview
Aviv Scientific specializes in addressing age-related cognitive and functional decline through novel applications of hyperbaric medicine. The company's core technology involves a proprietary personalized program that combines hyperbaric oxygen therapy (HBOT) with cognitive and physical training. Aviv Scientific serves the healthcare market, particularly healthy aging adults, aiming to enhance cognitive and physical performance. It operates within the Health Tech & Life Sciences sector, focusing on digital healthcare and digital therapeutics.
Strategic signal
In March 2023, Aviv Clinics highlighted a new study demonstrating the potential of hyperbaric oxygen therapy to bring hope to fibromyalgia patients. This signals the company's ongoing commitment to clinical research and expanding the therapeutic applications of its core technology, potentially opening new market segments and validating its approach to chronic conditions.
Log in to access full profile ›Company Intelligence Q&A
- What is Aviv Scientific's primary focus?
- Aviv Scientific focuses on treating age-related cognitive and functional decline, utilizing hyperbaric medicine to enhance human performance and improve the aging process in healthy adults.
- When was Aviv Scientific founded?
- Aviv Scientific was founded in July 2017 by Shai Efrati, Jonathan Preminger, and Michael Lobel.
- What was a significant finding published in November 2020?
- In November 2020, a human study showed a reversal in the biology of aging, specifically telomere shortening and senescent cell accumulation, through hyperbaric oxygen therapy (HBOT).
- What was the focus of a study highlighted by Aviv Clinics in February 2022?
- In February 2022, Aviv Clinics highlighted a study indicating that hyperbaric oxygen therapy can improve symptoms and brain structure in veterans suffering from treatment-resistant PTSD.
- What was the outcome of the first Long COVID clinical trial presented by Aviv Clinics and Sagol Center in August 2022?
- In August 2022, Aviv Clinics and the Sagol Center for Hyperbaric Medicine and Research presented research findings from the first Long COVID clinical trial to show symptom relief.